EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Guardant Health's enterprise value is $2,180.0 Mil.
Guardant Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-433.3 Mil. Therefore, Guardant Health's EV-to-EBITDA for today is -5.03.
The historical rank and industry rank for Guardant Health's EV-to-EBITDA or its related term are showing as below:
GH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -138.6 Med: -36.57 Max: -4.42
Current: -5.03
During the past 8 years, the highest EV-to-EBITDA of Guardant Health was -4.42. The lowest was -138.60. And the median was -36.57.
GH's EV-to-EBITDA is ranked worse than 100% of 120
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.16
vs GH: -5.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-18), Guardant Health's stock price is $16.69.
Guardant Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.280. Therefore, Guardant Health's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Guardant Health EV-to-EBITDA Historical Data
The historical data trend for Guardant Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Guardant Health Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBITDA
-121.35
-53.46
-29.53
-5.12
-8.02
Guardant Health Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
-5.12
-4.56
-9.39
-9.58
-8.02
Competitive Comparison
For the Diagnostics & Research subindustry, Guardant Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health EV-to-EBITDA Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Guardant Health's EV-to-EBITDA falls into.
Guardant Health EV-to-EBITDA Calculation
Guardant Health's EV-to-EBITDA for today is calculated as:
Guardant Health's current Enterprise Value is $2,180.0 Mil.
Guardant Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-433.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (NAS:GH) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Guardant Health's PE Ratio for today is calculated as:
Guardant Health's share price for today is $16.69.
Guardant Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.280.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Guardant Health's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health (Guardant Health) Business Description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GH has been successfully added to your 